An observational study in Cancer of the Head and Neck and Radiotherapy, sponsored by University of Vermont. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-04.
Sponsored by University of Vermont · Observational
This study will evaluate the role of cyclooxygenase pathways in radiation-induced and chemoradiation-induced mucositis.
Oral mucositis is a significant toxicity of radiation therapy and chemoradiation therapy in head and neck cancer patients. However the mechanisms that induce such mucositis are not completely understood. Previous work evaluating mucositis in bone marrow transplant patients has suggested that prostaglandin levels may be associated with the appearance of mucositis.
The present study will measure the levels in saliva of the prostaglandins PGE2 and PGI2 before, during, immediately after, and several weeks after radiotherapy for head and neck cancer. These salivary levels will be correlated with clinical observation of mucositis and patient reporting of pain levels.
Improved understanding of the mechanism of mucositis may lead to the development of more effective targeted agents to prevent this problem.
2,403 studies on the registry are indexed under Head and Neck Neoplasms; 559 are open to participants now.
This study's enrollment of 9 is below the median of 100 across 453 observational studies indexed under Head and Neck Neoplasms.
Browse Head and Neck Neoplasms studies →University of Vermont is the lead sponsor of 221 studies on the registry; 27 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients receiving radiotherapy or chemoradiotherapy for oral cancers. Consecutive patients will be invited to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
Salivary levels of PGE2 and PGI2 during and after radiotherapy
Time frame: 10 weeks after initiation of therapy
Observed mucositis during and after radiotherapy
Time frame: 10 weeks after initiation of radiotherapy
Patient reports of oral pain during and after radiation therapy
Time frame: 10 weeks after initiation of radiotherapy
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.